A detailed history of Winning Points Advisors, LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Winning Points Advisors, LLC holds 89,396 shares of IBRX stock, worth $234,217. This represents 0.48% of its overall portfolio holdings.

Number of Shares
89,396
Previous 92,786 3.65%
Holding current value
$234,217
Previous $498,000 33.53%
% of portfolio
0.48%
Previous 0.76%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.32 - $6.7 $11,254 - $22,713
-3,390 Reduced 3.65%
89,396 $331,000
Q4 2023

Nov 14, 2024

BUY
$1.25 - $5.21 $4,237 - $17,661
3,390 Added 3.79%
92,786 $465,000
Q3 2023

Nov 14, 2024

SELL
$1.29 - $3.1 $4,373 - $10,509
-3,390 Reduced 3.65%
89,396 $151,000
Q2 2023

Nov 14, 2024

SELL
$1.53 - $6.41 $242,352 - $1.02 Million
-158,400 Reduced 63.06%
92,786 $257,000
Q1 2023

Apr 21, 2023

BUY
$1.35 - $4.78 $11,610 - $41,108
8,600 Added 3.55%
251,186 $461,000
Q4 2022

Feb 10, 2023

SELL
$4.35 - $6.77 $39,019 - $60,726
-8,970 Reduced 3.57%
242,586 $1.23 Million
Q3 2022

Oct 07, 2022

BUY
$3.65 - $6.43 $53,290 - $93,878
14,600 Added 6.16%
251,556 $1.39 Million
Q2 2022

Aug 15, 2022

BUY
$2.68 - $6.14 $473,904 - $1.09 Million
176,830 Added 294.1%
236,956 $879,000
Q1 2022

Apr 27, 2022

BUY
$5.05 - $7.53 $303,636 - $452,748
60,126 New
60,126 $339,000
Q4 2021

Feb 16, 2022

SELL
$5.67 - $10.18 $249,241 - $447,492
-43,958 Closed
0 $0
Q3 2021

Nov 17, 2021

BUY
$9.17 - $14.24 $22,769 - $35,357
2,483 Added 5.99%
43,958 $428,000
Q2 2021

Aug 16, 2021

BUY
$13.41 - $22.4 $19,779 - $33,040
1,475 Added 3.69%
41,475 $593,000
Q1 2021

May 13, 2021

BUY
$12.83 - $42.25 $513,200 - $1.69 Million
40,000 New
40,000 $974,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.05B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Winning Points Advisors, LLC Portfolio

Follow Winning Points Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winning Points Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Winning Points Advisors, LLC with notifications on news.